Establishment Labs (NASDAQ:ESTA) Given New $72.00 Price Target at Canaccord Genuity Group

Establishment Labs (NASDAQ:ESTA) had its target price boosted by Canaccord Genuity Group from $60.00 to $72.00 in a research report released on Thursday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

A number of other analysts also recently issued reports on ESTA. BTIG Research raised their price objective on Establishment Labs from $62.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday. Needham & Company LLC increased their target price on shares of Establishment Labs from $48.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research report on Tuesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Establishment Labs in a report on Wednesday, October 8th. Finally, Mizuho increased their price objective on shares of Establishment Labs from $70.00 to $85.00 and gave the stock an “outperform” rating in a research report on Thursday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $66.71.

Establishment Labs Stock Performance

Shares of Establishment Labs stock traded up $0.09 during mid-day trading on Thursday, hitting $65.00. The stock had a trading volume of 1,048,731 shares, compared to its average volume of 571,818. The company has a debt-to-equity ratio of 9.71, a quick ratio of 1.67 and a current ratio of 2.84. The firm has a 50-day moving average of $44.13 and a two-hundred day moving average of $40.41. Establishment Labs has a 12-month low of $26.56 and a 12-month high of $65.45.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.16. The company had revenue of $53.78 million during the quarter, compared to analyst estimates of $52.28 million. Establishment Labs had a negative return on equity of 201.85% and a negative net margin of 43.45%.The firm’s revenue for the quarter was up 33.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.59) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. Research analysts predict that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

A number of hedge funds have recently added to or reduced their stakes in the business. State of Wyoming purchased a new stake in shares of Establishment Labs during the third quarter worth $71,000. ANTIPODES PARTNERS Ltd purchased a new stake in Establishment Labs during the 1st quarter worth about $81,000. Osaic Holdings Inc. raised its position in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares in the last quarter. CWM LLC boosted its stake in shares of Establishment Labs by 45.9% in the 2nd quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after buying an additional 686 shares during the period. Finally, Brian Low Financial Group LLC acquired a new position in shares of Establishment Labs during the third quarter worth about $223,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.